Navigation Links
Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Date:9/17/2009

apies that help patients get to a healthier blood pressure range," said John Flack, M.D., Valturna investigator, and Chairman of the Department of Internal Medicine, Wayne State University, Detroit. "Now for the first time, we have a treatment option in one pill that targets two key points of the RAAS, which may be overactive in many hypertensive patients."

This approval was primarily based on a pivotal eight-week randomized, double-blind, placebo-controlled clinical trial in approximately 1,800 patients, which studied aliskiren 150 mg and 300 mg and valsartan 160 mg and 320 mg alone and in combination. The initial doses of aliskiren and valsartan were 150 mg and 160 mg, respectively, and were increased at four weeks to 300 mg and 320 mg, respectively. Blood pressure reductions with the aliskiren/valsartan combination were significantly greater than with the monotherapies or placebo at the eight-week primary endpoint. Mean systolic and diastolic blood pressure reductions from baseline were 17.2/12.2 mmHg for aliskiren 300 mg/valsartan 320 mg, compared with 12.8/9.7 mmHg for valsartan 320 mg, 13.0/9.0 mmHg for aliskiren 300 mg, and 4.6/4.1 mmHg for placebo (p<0.05 for aliskiren/valsartan vs monotherapies or placebo).

The single-pill combination Valturna targets the RAAS in two ways. The valsartan component blocks, at the receptor level, the action of angiotensin II, an important end product of the RAAS that causes blood vessels to tighten and narrow. The aliskiren component reduces angiotensin II levels by directly inhibiting renin, an enzyme produced by the kidneys that starts a process which leads to formation of angiotensin II. An overactive RAAS is an important contributor to high blood pressure in many patients. By targeting two key points within the RAAS, Valturna helps blood vessels relax and widen so blood pressure is lowered.

Research suggests that up to 85% of hypertensive patients may need multip
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
2. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
5. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
6. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
7. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
8. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
9. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
10. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
11. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Rhythm, a biopharmaceutical ... genetic deficiencies that result in metabolic disorders, announced today ... S-1 with the U.S. Securities and Exchange Commission (SEC) ... of its common stock. The number of shares to ... have not yet been determined. Citigroup and ...
(Date:8/27/2014)... Dallas, TX (PRWEB) August 27, 2014 ... professional and in-depth study on the current state of ... The report provides a basic overview of the industry, ... analysis and Chinese domestic market analysis are provided with ... of the market. A comparison between the international and ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 “We are ... technology vendors,” said Ven Thangaraj, CEO of Radiant Sage. ... that are taking the imaging corelab market to a ... corelabs and research organizations to efficiently and effectively manage ... the data to be analyzed and read by trained ...
(Date:8/27/2014)... -- Research and Markets  has announced the addition ... Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... mass spectrometer industry. The report provides a ... and industry chain structure. The isotope ratio mass spectrometer ...
Breaking Biology Technology:Rhythm Files Registration Statement for Proposed Initial Public Offering 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2
... Calif., Aug. 30 Cepheid (Nasdaq:,CPHD) will present ... at the Four Seasons Hotel, Boston, September 5 ... and Senior Vice President, Finance and,Chief Financial Officer, ... ET on,September 7. The webcast, along with ...
... Aug. 30 Verenium,Corporation (Nasdaq: VRNM ), a ... the development of high-performance specialty,enzymes, announced today that Carlos ... be presenting at the Cowen and Company Clean,Energy Conference. ... ET,on Thursday, September 6, 2007 and will take place ...
... 30 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... and CEO will present at the 2007 UBS ... the Grand Hyatt New York on Wednesday,September 26 ... ) A live webcast of the presentation ...
Cached Biology Technology:Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 3Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 2
(Date:8/27/2014)... that a single fungal cell or bacterial colony exerts on ... a heavy role in setting up some of the most ... be too much of a stretch to say that plants ... respond to the touch of beneficial fungi, according to a ... at the University of Wisconsin-Madison. , "Many people have ...
(Date:8/27/2014)... 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... in the offering consists of 2,000 shares of common ...
(Date:8/27/2014)... Most of North America,s megafauna mastodons, short-faced bears, ... horses disappeared close to 13,000 years ago at ... this massive extinction has long been debated by scientists ... , A group of scientists, including UC Santa Barbara,s ... Science, posited that a comet collision with Earth played ...
Breaking Biology News(10 mins):A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Nanodiamonds are forever 2Nanodiamonds are forever 3
... emissions of fossil carbon and the resulting increase in temperature ... age. According to new research from the University of Gothenburg, ... having the opposite effect. "We are probably entering ... it due to the effects of carbon dioxide", says researcher ...
... did you put your keys last night? Who was the ... neurons in your brain are currently sending electromagnetic rhythms through ... to each of these questions. Researchers in Drexel,s School of ... rare look inside the brain to discover the exact pattern ...
... Wisconsin researchers have taken skin from patients and, using ... a laboratory model for an inherited type of macular ... McPherson Eye Research Institute, said that while Best disease ... eye disease, which destroys the macula of the retina, ...
Cached Biology News:Carbon dioxide - our salvation from a future ice age? 2Making memories: Drexel researchers explore the anatomy of recollection 2Making memories: Drexel researchers explore the anatomy of recollection 3Cells from skin create model of blinding eye disease 2
... cell culture chambered coverslips are ... for staining and imaging. The ... gaskets with standard optical-quality coverslips ... ready to use. Preassembled CultureWell ...
... Holds 0.1 mL - 25 mL pipets ,Angled ... accommodates most standard square or round pipet cans. Constructed ... compartments, each 76 mm W x 76 mm H ... 3/8 ins.). Overall dimensions: 89 mm W x 406 ...
... CultureWell cell culture systems provide an ... for staining and imaging. Each system ... standard optical-quality coverslips in cell culture ... sterile and ready to use. Individual ...
Request Info...
Biology Products: